Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.90 -2.23% 39.50 39.50 40.20 39.60 39.40 39.50 1,302,574 16:29:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 11.4 180

Ekf Diagnostics Share Discussion Threads

Showing 3326 to 3349 of 4475 messages
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older
DateSubjectAuthorDiscuss
20/4/2021
08:48
Shanklin...Recall the point I raised yesterday that EKF is supplying the picks & shovels to the Covid opportunity - Source BioScience to use PrimeStore MTM kits for COVID-19 testing service EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted point-of-care business, announces that it has signed an agreement with Source BioScience UK Ltd (“Source BioScience”), which provides Laboratory testing services for the NHS, to supply PrimeStore MTM, a novel patented sample collection device, to be used for its growing COVID-19 testing service. hTTps://www.sourcebioscience.com/news/source-bioscience-to-use-primestore-mtm-kits-for-covid-19-testing-service/ That is already been applied elsewhere too, e.g myhealthchecked/boots etc, but I also think there is a very good chance of securing other business, including opportunities outside of and beyond Covid testing.
wan
20/4/2021
08:24
As an EKF novice it is quite difficult to assess EKF's competitive position in a market which many companies will: - attempt to win a chunk of PHE's 15Bn as per post 1754 - be offering super-duper mobile diagnostic centres Obviously there is a lot for EKF to target but no certainty as to how much business they will win... ...or perhaps you guys are more certain. EKF does not have to win that high a proportion of all this for it to be transformative for the company.
shanklin
20/4/2021
08:15
Re testing, it's also worth taking on board EKF's 'global' roll-out of their point-of-care CE marked, FDA CLIA-waived STAT siteĀ® WB analyser, which is underway. Staying with testing - Covid-19 Mobile Testing laboratory services available for large volume, fast testing to meet requirements. Whether it is for a sporting events, theatres, concert venues or television studios; we are able to offer a tailored solution. hTTps://www.sourcebioscience.com/covid-19-testing-services/mobile-testing-units/
wan
19/4/2021
21:34
FYI - 18th April https://bidstats.uk/tenders/2021/W15/749076498 Description Lot 4 – Clinical Laboratory Diagnostic Testing Services is intended to enable access to Clinical Laboratory Diagnostic Testing Services using extant techniques and allow for the addition of new techniques or existing techniques utilised in a new manner in the future. The Lot is to ensure that there are consistent and affordable provision of high quality, safe and compliant Testing Services which should be delivered efficiently and effectively to support wider clinical services. Please note that this Award Notice is for Lot 4 however the Framework Agreement encompasses the following four lots: - Lot 1: Diagnostic Goods and Services - Lot 2: Research and Development Goods and Services - Lot 3: Manufacturing, Product Development and Commercialisation - Lot 4: Clinical Laboratory Diagnostic Testing Services
mirandaj
19/4/2021
15:39
+1 for replayable investor presentations. PI World & InvestorMeetCompany both provide an excellent service
crazycoops
19/4/2021
12:21
Thank you wan Sounds potentially very exciting. It would certainly be helpful for EKF to present via someone like PIWorld so all investors (or potential investors) had ready access to replays of corporate presentations. I hadn't picked up on EKF until you, on this thread, and several others I communicate with via Twitter were obviously so excited about the recent results presentation; its a shame the rest of us cannot replay it.
shanklin
19/4/2021
12:03
Shanklin... During the recent Presentation meeting, Julian Baines (CEO) described EKF as supplying the picks & shovels to the Covid opportunity and described it as making the 'real' money. I also took note of him saying just after that comment, that EKF will/would/could (not sure which as I could not take notes quickly enough) become one of the world's major manufacturers of test kits. I think he was also referring to the manufacture/assembly of home-use testing kits, and I assume such test kits being used beyond that of testing just the employees of the recently announced private sector partner (but again, those 1m + employees should not be underestimated, in terms of volumes, and perhaps not just for Coronavirus testing). In my view, home-use testing (via postal, or courier, or via certain logistical delivery/collection service!) also sits quite well with the digital health/telehealth opportunity. So perhaps EKF could indeed become an important supplier of the picks & shovels in the form of numerous home-use tests that will also compliment digital/telehealth, not to mention pandemic/epidemic preparedness.
wan
19/4/2021
11:03
wan If (and I don't know if its true) EKF needs less super-duper labs than ALL? of it competitors, presumably it will be able to offer a price/timescale that none of its competitors can match on a profitable basis. Were that the case, and EKF and partners were able to meet market demand, it would become the dominant supplier. Perhaps I am being simplistic.
shanklin
19/4/2021
08:04
EKF is not mentioned in the following IC article, but readers will get the drift - Ideas Farm: Is a Big Tech healthcare revolution on its way? This week, Microsoft announced a $20bn deal to acquire a healthcare AI specialist April 15, 2021 By Nilushi Karunaratne Microsoft’s recent M&A focus has been on gaming and social media, but Wedbush analyst Daniel Ives sees the blockbuster Nuance deal as the start of a “more aggressive chapter of cloud growth”. Indeed, it is laying down the gauntlet in the cloud wars with Amazon and Alphabet, which are also trying to push into healthcare. For their western counterparts, healthcare is still a small part of the overall earnings picture. But there are substantial long-term growth opportunities on offer and the tech giants’ deep pockets could enable them to become a substantial force for disruption. So, while a revolution may not be imminent, the wheels are certainly in motion. Full story - hTTps://www.investorschronicle.co.uk/ideas/2021/04/15/ideas-farm-is-a-big-tech-healthcare-revolution-on-its-way/
wan
17/4/2021
13:43
Folks may find this interview of interest. It is between the High Sheriff of Herefordshire and Kate Bingham the Chair of the committee that orchestrated the UK's vaccine approach. Reference to Jesse is Jesse Norman MP for Hereford. hTTps://podcasts.apple.com/gb/podcast/bench-talk/id1562663358
welshborderer
16/4/2021
09:24
Shanklin...What I also recently found quite interesting, was that approaching half (57 out of 136) of the Governments listed providers of day 2 and day 8 coronavirus testing for international arrivals, are partnered with Oncologica - hTTps://www.gov.uk/guidance/providers-of-day-2-and-day-8-coronavirus-testing-for-international-arrivals
wan
16/4/2021
08:18
wan Interesting stuff, thank you. At least we can be reasonably confident that sales through Onconlogica aren't lower than planned for.
shanklin
16/4/2021
07:59
Edit to the above post to include - 2021 Outlook slide And Oncologica's test booking page.
wan
16/4/2021
07:46
Recall the following from EKF's recent Presentation 2021 Outlook slide - Continued demand for PrimeStore MTM tubes and bulk medium • £2.49m of orders to Ireland in Q1 (versus £5.2m in 2020) • £3m+ of orders in-house from Concepta, Oncologica and PHE Manchester I note that Oncological put the following message up recently (in the last week) - We sincerely apologise to anyone experiencing difficulties contacting Oncologica, this is due to an unprecedented increase in Covid testing enquiries and kit orders received since government travel rules were introduced. To handle the thousands of increased test bookings, we have introduced automated messaging on our switchboard to direct callers to a Frequently Asked Questions guide for travel testing on our Covid-19 test webpages. We have also increased our call centre support team capacity. Our postal/courier partners have also encountered issues with the increased test kit deliveries. Although their service quality is outside of our direct control, we are liaising closely with them to return to prompt and reliable service. We very much regret any difficulties customers have experienced and assure you of our continued commitment to supporting your lab testing needs. hTTps://covid19.oncologica.com/service-delays-working-to-improve-our-support/ And you can still book tests - hTTps://covid19.oncologica.com/ And as we know, post that Presentation update, Boots are now also including PrimeStore MTM in their test kits (via Myhealthchecked/Concepta), but not in just one particular test kit - Chris Helm, Executive Vice President Global Business Development at Longhorn Vaccines and Diagnostics made the following comment - 15hours ago Longhorn thanks Walgreens Boots for including PrimeStore MTM in their COVID-19 test kits including Boots' MyHealthChecked At-Home COVID-19 sample collection kit and also for their Fit To Fly program. Safe inactivated samples for PCR, sequencing and biobanking hTTps://www.linkedin.com/posts/chrishelm1_primestore-activity-6788483619015938048-_08N At the very least, solid demand that's not going to fade anytime soon!
wan
16/4/2021
07:22
https://www.theguardian.com/world/2021/apr/15/what-is-lateral-flow-covid-test-how-accurate
mirandaj
14/4/2021
12:36
New article today in the IC briefly mentions EKF and how "testing will only become more important – in turn drawing greater levels of investment": Https://www.investorschronicle.co.uk/news/2021/04/14/testing-demand-buoyed-by-lockdown-easing/ "Meanwhile, aided by Covid testing products including a sample containment device, EKF Diagnostics’ (EKF) full-year revenues rose almost a half to £65.3m."
rivaldo
14/4/2021
07:32
FYI https://www.randoxhealth.com/pcr-travel-tests-reduced/
mirandaj
13/4/2021
07:31
Staying with large private sector operators - Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative Apr 12, 2021 | staff reporter NEW YORK – Amazon said on Monday that it is launching the next phase of its Amazon Web Services (AWS) Diagnostic Development Initiative, in which it plans to distribute $12 million this year to fund projects for SARS-CoV-2 testing, as well as for other infectious disease diagnostics. AWS also said it will prioritize COVID-19 projects but will also evaluate projects focused on other infectious diseases. The company will accept applications through the end of the year, with priority given to applications received before July 31. "We have seen transformative innovations in how we diagnose disease over the past year, from machine learning-powered X-ray imagery analysis to new developments in rapid, high quality, and direct-to-consumer tests," Vin Gupta, chief medical officer of Amazon's COVID-19 response unit, said in a statement. "These changes will continue to evolve and improve our ability to respond to future outbreaks. We have already seen inspirational results from the Diagnostic Development Initiative, and we look forward to supporting broader uses of cloud technologies to enable organizations and communities to identify and respond even faster to future outbreaks." Full story - hTTps://www.360dx.com/diagnostics/amazon-give-out-12m-under-next-phase-aws-diagnostics-development-initiative#.YHUlm-hKiF4
wan
13/4/2021
07:27
Excerpt from Source Bio's Results announcement this morning - COVID-19 testing market backdrop A very large proportion of the Group's business in 2020 was derived from high volume laboratory based COVID-19 Antigen RT-PCR testing, the Group's only COVID-19 offering. The Board is mindful that the COVID-19 landscape is rapidly evolving and that this brings both uncertainty and opportunity. The Group believes that, whilst PCR based testing will likely remain the gold standard, it will be essential for the Group to offer additional testing services during 2021 and beyond. There has already been a shift in focus from many customers towards screening initiatives using rapid lateral flow testing, as one example - the need for testing is clearly evolving and expanding. The Group has reviewed and validated a number of complementary testing applications, technologies and routes to market and will be launching these progressively, as evidenced by the announcement of the Group's collaboration with Oxford Nanopore in December 2020, which increases the Group's offering to include LamPORE rapid testing both in a traditional laboratory setting and in mobile trailers to provide for more localised community focused testing. It is therefore expected that the Group's COVID-19 testing focus in 2021 will transition from exclusively RT-PCR testing to a wide portfolio of offerings, including rapid testing. Indeed, the Group has already seen multiple COVID-19 revenue streams in the first quarter of 2021, including revenues generated from mobile based testing units operated on behalf of the DHSC and Mitie. The Group has established a number of new COVID-19 testing initiatives, some of which are in anticipation of the expected lifting of travel restrictions, where significant business is expected to be secured as travel related testing gains momentum. The Group also recently announced the configuring of its San Diego facility to provide COVID-19 testing services to the USA market. This is expected to launch mid-year which, together with the seasonal nature of travel, means that the Group anticipates a significant proportion of 2021 revenues and earnings to be generated from the third quarter of the year onwards, giving a second half bias to the expected results for 2021. SourceBio is actively planning for demand for COVID-19 testing services to continue potentially longer than was initially anticipated at the start of the pandemic and before the multiple waves of infections and emergence of new virus variants. Whilst the vaccination roll-out to date has been very successful, the Group believes that this will not negate the ongoing need for testing. Indeed, a recent analysis in the US and a number of European countries completed by the Boston Consulting Group concluded " . . . with peak demand occurring in the seasonally affected first quarters of 2021 and 2022. Although we expect testing volumes to decline after 2021, we expect a continued need for testing in 2023 and 2024 as the disease enters a more endemic phase". Airports, airlines, cruise lines and hotels are already looking to establish testing services for passengers and guests. Similarly, the sports and entertainment industries are also building on-site testing capabilities and tests are expected to continue to be sold in leading high street pharmacy outlets. Outlook The Group has been through a transformational year in 2020 and starts the new year with a strong cash balance, no borrowings, and a business that is rapidly growing whilst generating substantial earnings and cash. Trading in the early months of 2021 has been solid and in line with the Board's expectation. The Group is working hard in all the COVID-19 testing initiatives described above and the Board believes the Group is well placed to capture attractive new business opportunities. The Board also believes that its long-standing three business units, Healthcare Diagnostics, Genomics and Stability Storage offer both near-term and longer-term sustained growth potential. Whilst elective surgeries continue to be significantly and quite publicly delayed, the backlog of potential work for our Cellular Pathology teams appears to be growing very substantially. Whilst the timing of a return to substantial volumes of work cannot be accurately predicted, the Board believes that the volumes will be very high when they do return, and the teams have prepared plans to cope with the significant volume growth expected in due course. Given the current macro environment, the Board believes that SourceBio is well positioned to deliver further substantial growth in revenue, earnings and cash generation in 2021. It will also continue to consider potential acquisition opportunities. We look forward to updating shareholders further during the year. Full Results Announcement - hTTps://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-Final-Results/84807273 So, as some of us recognised, coronavirus testing will indeed be with us for a very long time! And with EKF reporting continued demand for PrimeStore MTM tubes and bulk medium, and now also PBS, that aligns quite neatly with what Source Bio are seeing in terms of longevity, as well as noting the interest from large private sector operators, in terms of providing testing requirements. Not to mention that EKF's new lines of business and commercial partnerships, will add further to the mix of revenues sources and growth.
wan
13/4/2021
07:11
Welshborder...FYI, We have discussed/dissected that article over the previous two days.
wan
13/4/2021
06:41
Can he provide this weeks winning lottery numbers too? These finance experts are just trying to look smart - with "trying" the operative word. I have no idea where price is going next and nor does anyone else
davr0s
13/4/2021
02:24
Justin Urquhart Stewart is forecasting a pullback on the shares whilest being supportive of the company, I think. hTTps://www.thisismoney.co.uk/money/investing/article-9454835/MR-MONEY-MAKER-EKF-Diagnostics-boost-portfolio.html
welshborderer
12/4/2021
08:40
Edit/tweaks to the above post. Plus, I forgot to mention that there is also recruitment for a 3rd shift in one of Amazons US labs, also known as the night shift or graveyard shift, which is usually associated with 24 hour operation.
wan
11/4/2021
09:10
wan...thank you for your very insightful comment.
nurdin
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220924 19:15:43